Blood Res.  2018 Sep;53(3):183-184. 10.5045/br.2018.53.3.183.

Multiple myeloma in Korea: risk stratification and initial treatment

• Yoon SS

• KMID: 2429312
• DOI: http://doi.org/10.5045/br.2018.53.3.183

Abstract

No abstract available.

MeSH Terms

Korea*
Multiple Myeloma*

Reference

1. Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009; 84:1095–1110. PMID: 19955246.

2. Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014; 28:269–277. PMID: 23974982.

3. Lionetti M, Neri A. Utilizing next-generation sequencing in the management of multiple myeloma. Expert Rev Mol Diagn. 2017; 17:653–663. PMID: 28524737.

4. Joseph NS, Gentili S, Kaufman JL, Lonial S, Nooka AK. High-risk multiple myeloma: definition and management. Clin Lymphoma Myeloma Leuk. 2017; 17S:S80–S87. PMID: 28760306.

5. Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016; 91:719–734. PMID: 27291302.

6. Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016; 91:101–119. PMID: 26763514.

7. Boyd KD, Ross FM, Chiecchio L, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012; 26:349–355. PMID: 21836613.

8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Multiple myeloma. Washington, PA: National Comprehensive Cancer Network;2018. Accessed June 3, 2018. at https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf.

9. Byun JM, Shin DY, Hong J, et al. Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients. Cancer Med. 2018; 7:831–841. PMID: 29380550.